ImmuPharma (LON:IMM) Shares Down 4.5% – Here’s Why

ImmuPharma plc (LON:IMMGet Free Report)’s stock price was down 4.5% during mid-day trading on Wednesday . The stock traded as low as GBX 2.82 ($0.03) and last traded at GBX 2.94 ($0.04). Approximately 2,099,809 shares traded hands during trading, a decline of 89% from the average daily volume of 19,547,262 shares. The stock had previously closed at GBX 3.08 ($0.04).

ImmuPharma Price Performance

The company has a 50-day simple moving average of GBX 1.65 and a 200-day simple moving average of GBX 1.70. The firm has a market cap of £11.83 million, a PE ratio of -284.00 and a beta of 1.53.

About ImmuPharma

(Get Free Report)

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

See Also

Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.